IFNG and neoplasm: A study found that in patients receiving immunotherapy, tumor cells can downregulate or alter IFN-γ signaling pathways such as loss-of-function alleles of genes encoding for JAK1/2, and changes in STAT1 to escape the influence of IFN-γ [38], resulting in poor efficacy and resistance.